期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨质疏松症治疗新药特立帕肽 被引量：8

暂未订购
导出
摘要 骨质疏松症治疗目前以抑制骨吸收药物为主,而特立帕肽(teriparatide)作为一种促进骨形成的新药,经过多年临床研究证实对各类骨质疏松症有较好的疗效,可与大多数抗骨吸收药物联用并呈现协同作用。此外,本品在原发性甲状旁腺机能减退症诊治中亦显示较好的应用前景。
作者 张颖 彭永德
机构地区 上海交通大学附属第一人民医院内分泌科
出处 《世界临床药物》 CAS 2004年第12期725-729,共5页 World Clinical Drug
关键词 治疗 骨质疏松症 新药 特立帕肽 药物联用 甲状旁腺机能减退症 抑制骨吸收药物 促进 协同作用
分类号 R681 [医药卫生—骨科学] R97 [医药卫生—药品]
  • 相关文献

参考文献5

  • 1王洪复,金慰芳,高建军,顾淑珠,周轶,孙爱龙,胡菲,沈洁,张顺昌.重组人甲状旁腺激素_(1-34)对去卵巢大鼠骨质疏松的治疗作用[J].中国医学科学院学报,2003,25(3):275-279. 被引量：25
  • 2Chad Deal MD. The use of intermittent human parathyroid hormone as a treatment for osteoporosis[J] 2004,Current Rheumatology Reports(1):49～58
  • 3Q. Rehman,T.F. Lang,C.D. Arnaud,G.W. Modin,N.E. Lane. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis[J] 2003,Osteoporosis International(1):77～81
  • 4N. E. Lane,S. Sanchez,H. K. Genant,D. K. Jenkins,C. D. Arnaud. Short-Term Increases in Bone Turnover Markers Predict Parathyroid Hormone-Induced Spinal Bone Mineral Density Gains in Postmenopausal Women with Glucocorticoid-Induced Osteoporosis[J] 2000,Osteoporosis International(5):434～442
  • 5T. Fujita,T. Inoue,H. Morii,R. Morita,H. Norimatsu,H. Orimo,H. E. Takahashi,K. Yamamoto,M. Fukunaga. Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose Levels[J] 1999,Osteoporosis International(4):296～306

二级参考文献11

  • 1Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in Primary hyperparathyroidism. J Bone Miner Res,1989, 4:281-291.
  • 2Rubin Mr, Cosman F, Lindsay IL et al. The anabolic effects of parathyroid hormone. Osteoporos Int, 2002, 13:267-277.
  • 3Ejersed C, Andeassen TF, Hauge EM, et al. Parathyroid bormone(1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone, 1995, 17(6):507-511.
  • 4Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology, 2002, 143:3230-3242.
  • 5Okimoto N, Tsurukami H, Okazaki Y, et al. Effects of a weekly injection of human parathyroid hormone(1-34) and withdrawal on bone mass, stxength, and tumover in mature ovariectomized rats. Bone, 1998, 22:523-531.
  • 6Brommage R, Hotchkiss CE, Lces CJ, et al. Daily treatment with human recombinant parathyroid hormone(1-34) LY333334,for l year increases bone mass in ovariectomized monkeys.J Clin Endocrinol Metab, 1999. 84(10):3757-3763.
  • 7Sato M, Weatmore M, Clendenon J, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumber vertebrate of ovariectomized cynomolgus macaques. Osteoporm lnt, 2000, 11(10):871-880.
  • 8Ma YL, Cain RI, Helladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology,2001, 142:4047-4054.
  • 9Locklin RM, Khosla S, Riggs BL. Mechanism of biphasic and catabolic effects of parathyroid hormone(PTH) on bone cells. Bone, 2001, 28 (Suppl):580.
  • 10Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest, 1999, 104:439-446.

共引文献24

同被引文献124

引证文献8

二级引证文献80

世界临床药物
2004年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部